Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial

Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS ≤ 25). We tested whether combined results from RS and the sensitivity to endocrine therapy (SET2...

Descripción completa

Detalles Bibliográficos
Autores principales: Speers, Corey W., Symmans, W. Fraser, Barlow, William E., Trevarton, Alex, The, Stephanie, Du, Lili, Rae, James M., Shak, Steven, Baehner, Rick, Sharma, Priyanka, Pusztai, Lajos, Hortobagyi, Gabriel N., Hayes, Daniel F., Albain, Kathy S., Godwin, Andrew, Thompson, Alastair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082279/
https://www.ncbi.nlm.nih.gov/pubmed/36649570
http://dx.doi.org/10.1200/JCO.22.01499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082279/
https://www.ncbi.nlm.nih.gov/pubmed/36649570
http://dx.doi.org/10.1200/JCO.22.01499

Ejemplares similares